Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medicus Pharma Ltd. Common Stock (MDCX)
USD0.35
-0.02 (-4.23%)
CA NASDAQ Healthcare Biotechnology
Address
300 Conshohocken State Rd. Suite 200 19428
W. Conshohocken, CA
W. Conshohocken, CA
CEO
Raza Bokhari
Website
medicuspharma.com
IPO
2024-11-15
CIK 1997296 ISIN CA58471K2020
Also trades on
NASDAQ Capital Market · MDCX (USD)
NASDAQ Capital Market · MDCXW (USD)
Description
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.35
-0.02 (-4.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
-0.65
Float Shares
4.36M
Free Float %
19.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.28% | +9.24% | -16.38% | -68.21% | -84.68% | -77.97% | -94.67% | -87.28% | -87.28% | -87.28% | -87.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.35
DCF (Unlevered)
0.08
-76.3%
DCF (Levered)
0.27
-21.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-28.95
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-78.2% Q1'26: +26.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+79.7% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.22× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
49.4K
49.4K – 49.4K
|
—
— – —
-100.0% YoY
|
31.32M
31.32M – 31.32M
|
118.67M
118.67M – 118.67M
+278.9% YoY
|
289.07M
289.07M – 289.07M
+143.6% YoY
|
| EBITDA |
-11.16M
|
-18.35M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.16M
|
-18.35M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-11.16M
est: -10.24M (-8.9%)
|
-25.37M
est: -31.37M (+19.1%)
|
-10.10M
-10.28M – -9.74M
+67.8% YoY
|
-7.11M
-7.94M – -6.28M
+29.6% YoY
|
-5.38M
-5.38M – -5.38M
+24.4% YoY
|
4.58M
4.58M – 4.58M
+185.2% YoY
|
21.56M
21.56M – 21.56M
+370.8% YoY
|
| SGA |
7.65M
|
17.92M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.10
est: -1.06 (-3.3%)
|
-1.96
est: -1.82 (-8.0%)
|
-0.58
-0.59 – -0.56
+67.8% YoY
|
-0.41
-0.46 – -0.36
+29.6% YoY
|
-0.31
-0.31 – -0.31
+24.4% YoY
|
0.27
0.27 – 0.27
+185.2% YoY
|
1.25
1.25 – 1.25
+370.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-20 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
977.4K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-12 vs prev Q
New positions
1
Closed positions
13
Increased
6
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | INTERCHANGE CAPITAL PARTNERS, LLC | 1.66M +75.0K (+4.7%) | 6.18M +3.8M (+154.6%) | 9.62% +0.434 pp | 1.95% +1.502 pp | USD2.49 -81.5% | 6 qtrs — |
| 2 | PRIVATE ADVISOR GROUP, LLC | 240.1K +64.6K (+36.8%) | 110.2K -158.3K (-59.0%) | 1.39% +0.374 pp | 0.00% -0.001 pp | USD2.32 -80.2% | 5 qtrs — |
| 3 | BRYN MAWR TRUST CO | 51.2K +— (+0.0%) | 23.5K -54.9K (-70.0%) | 0.30% +0.000 pp | 0.00% -0.001 pp | USD1.92 -76.0% | 3 qtrs — |
| 4 | MAY HILL CAPITAL, LLC | 50.6K +15.0K (+42.1%) | 23.2K -31.3K (-57.4%) | 0.29% +0.087 pp | 0.01% -0.008 pp | USD1.73 -73.4% | 4 qtrs — |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 48.1K +19.7K (+69.0%) | 22.1K -21.5K (-49.3%) | 0.28% +0.114 pp | 0.00% +0.000 pp | USD1.27 -63.8% | 3 qtrs — |
| 6 | UBS GROUP AG | 40.4K +27.2K (+205.7%) | 18.6K -1.7K (-8.3%) | 0.23% +0.157 pp | 0.00% +0.000 pp | USD1.15 -60.0% | 5 qtrs — |
| 7 | LPL FINANCIAL LLC | 15.6K +15.6K (+100.0%) | 7.2K +7.2K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.000 pp | USD0.46 +0.0% | 3 qtrs — |
| 8 | SMITHFIELD TRUST CO | 11.5K -2.4K (-17.3%) | 5.0K -16.0K (-76.2%) | 0.07% -0.014 pp | 0.00% -0.001 pp | USD1.53 -69.9% | 2 qtrs — |
| 9 | BRAVE ASSET MANAGEMENT INC | 10.0K -10.0K (-50.0%) | 4.6K -26.0K (-85.1%) | 0.06% -0.058 pp | 0.00% -0.006 pp | USD2.32 -80.2% | 3 qtrs — |
| 10 | WELLS FARGO & COMPANY/MN | 75.00 +— (+0.0%) | 34.00 -81.0 (-70.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.99 -84.6% | 4 qtrs — |
| 11 | DAGCO, INC. | — -349.0 (-100.0%) | — -534.0 (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
13
Sells
0
Shares acquired
825.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+825,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | Smith Andrew Alasdair | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.50 | 25.0K | 50,000 | D | ↗ |
| 2026-03-30 | Rodgers Cathy McMorris | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Raju Ajay | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Mehmud Faisal | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.50 | 62.5K | 125,000 | D | ↗ |
| 2026-03-30 | May Sara R. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | MAHAFFY PATRICK J | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Kaiser Larry | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | FISHMAN BARRY | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Ciaruffoli Robert J. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Brennan Edward J. | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2026-03-30 | Bonner Carolyn F. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.50 | 50.0K | 100,000 | D | ↗ |
| 2026-03-30 | Bokhari Raza | Director / Officer | A-Award | A | Stock Option (right to buy) | 325,000 | 0.50 | 162.5K | 325,000 | D | ↗ |
| 2026-03-30 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.50 | 12.5K | 25,000 | D | ↗ |
| 2025-12-16 | Smith Andrew Alasdair | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.80 | 90.0K | 50,000 | D | ↗ |
| 2025-12-16 | Rodgers Cathy McMorris | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | Raju Ajay | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | Mehmud Faisal | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.80 | 135.0K | 75,000 | D | ↗ |
| 2025-12-16 | May Sara R. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | MAHAFFY PATRICK J | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | Kaiser Larry | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | FISHMAN BARRY | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | Ciaruffoli Robert J. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-12-16 | Brennan Edward J. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.80 | 90.0K | 50,000 | D | ↗ |
| 2025-12-16 | Bonner Carolyn F. | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.80 | 135.0K | 75,000 | D | ↗ |
| 2025-12-16 | Bokhari Raza | Director / Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 1.80 | 225.0K | 125,000 | D | ↗ |
| 2025-12-16 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.80 | 45.0K | 25,000 | D | ↗ |
| 2025-08-29 | MAHAFFY PATRICK J | Director | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 35,435 | D | ↗ |
| 2025-08-13 | Quinlan James P. | Officer | M-Exempt | A | Common Shares, no par value ("Common Shares") | 125,000 | 0.81 | 101.3K | 254,147 | D | ↗ |
| 2025-07-22 | Rodgers Cathy McMorris | Director | — | — | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 0 | D | ↗ |
| 2025-07-22 | Raju Ajay | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-07-22 | Quinlan James P. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.08 | 154.0K | 50,000 | D | ↗ |
| 2025-07-22 | Mehmud Faisal | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.08 | 154.0K | 50,000 | D | ↗ |
| 2025-07-22 | May Sara R. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-07-22 | Kaiser Larry | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-07-22 | FISHMAN BARRY | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-07-22 | Ciaruffoli Robert J. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-07-22 | Brennan Edward J. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.08 | 154.0K | 50,000 | D | ↗ |
| 2025-07-22 | Bonner Carolyn F. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.08 | 154.0K | 50,000 | D | ↗ |
| 2025-07-22 | Bokhari Raza | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 3.08 | 770.0K | 250,000 | D | ↗ |
| 2025-07-22 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 3.08 | 77.0K | 25,000 | D | ↗ |
| 2025-06-30 | Smith Andrew Alasdair | Officer | — | — | Stock Option (right to buy) | 100,000 | 2.60 | 260.0K | 0 | D | ↗ |
| 2025-05-20 | VELOCITY FUND PARTNERS, LP | 10% Owner | S-Sale | D | Medicus Pharma LTD | 75,000 | 7.72 | 578.9K | 3,248,741 | I | ↗ |
| 2024-12-31 | VELOCITY FUND PARTNERS, LP | 10% Owner | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 2,914,330 | I | ↗ |
| 2024-12-31 | Raju Ajay | 10% Owner | — | — | Common Shares | 0 | 0.00 | — | 2,000,000 | I | ↗ |
| 2024-12-31 | Quinlan James P. | Officer | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 129,147 | D | ↗ |
| 2024-12-31 | Melani Kenneth R. | 10% Owner | — | — | Common Shares | 0 | 0.00 | — | 409,411 | D | ↗ |
| 2024-12-31 | Mehmud Faisal | Officer | — | — | Stock Option (right to buy) | 100,000 | 2.26 | 226.0K | 0 | D | ↗ |
| 2024-12-31 | May Sara R. | Director | — | — | Stock Option (right to buy) | 25,000 | 2.32 | 58.0K | 0 | D | ↗ |
| 2024-12-31 | Lavelle Frank W | Director | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 25,622 | D | ↗ |
| 2024-12-31 | Kaiser Larry | Director | — | — | Stock Option (right to buy) | 25,000 | 0.81 | 20.3K | 0 | D | ↗ |
| 2024-12-31 | FISHMAN BARRY | Director | — | — | Stock Option (right to buy) | 25,000 | 0.81 | 20.3K | 0 | D | ↗ |
| 2024-12-31 | Ciaruffoli Robert J. | Director | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 12,500 | D | ↗ |
| 2024-12-31 | Brennan Edward J. | Officer | — | — | Stock Option (right to buy) | 75,000 | 0.81 | 60.8K | 0 | D | ↗ |
| 2024-12-31 | Bonner Carolyn F. | Officer | — | — | Stock Option (right to buy) | 10,000 | 2.75 | 27.5K | 0 | D | ↗ |
| 2024-12-31 | Bokhari Raza | Director / Officer | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 649,173 | I | ↗ |
| 2024-12-31 | Ashton William | Director | — | — | Common Shares, no par value ("Common Shares") | 0 | 0.00 | — | 1,250 | D | ↗ |
Executive team
Top executives
Shares Outstanding
22.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Faisal Mehmud | Chief Medical Officer | 538.4K | — |
| Edward J. Brennan Jr. | Chief Scientific Officer and Head of R&D Program | 479.4K | — |
| Raza Bokhari | Chief Executive Officer & Executive Chairman | 226.8K | — |
| Anna Baran-Djokovic | Senior Vice President of Investor Relations | — | female |
| Andrew Alasdair Smith | Chief Operating Officer | — | male |
| Maryann Adesso | Chief of Staff & Corporate Secretary | — | female |
| Viktoria Slepeniuk | Senior Vice President of Public Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDCX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
